Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

NCT02948569 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Metabolic Syndrome

Interventions

DRUG: 3-V Bioscience-2640

Sponsor

University of Missouri-Columbia

Collaborators

[object Object]